18 Boletín Hipertensión VOL 25. 2021 / 12 - 18 Hipertensión arterial y Síndrome metabólico Glosario de Abreviaciones ARA II : Bloqueadores del receptor de angiotensina 2 ARNm: Acido ribonucleico mensajero DLP: Dislipidemia DM 2 : Diabetes mellitus 2 HDLc: Colesterol de alta densidad HTA: Hipertensión arterial IECA.: Inhibidores de enzima angiotensina LDLc: Colesterol baja densidad OV: Obesidad visceral ON: Oxido nítrico PA: Presión arterial RCV: Riesgo cardiovascular RI o IR: Resistencia insulina, Insulino resistencia SAOS: Síndrome apnea obstructiva del sueño SM: Síndrome metabólico SNS: Sistema nervioso simpático SRAA: Sistema renina angiotensina aldosterona TGS: Triglicéridos Referencias 1. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991;14(3):173-94. 2. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37(12):1595-607. 3. Consenso Latinoamericano de la Asociación Latinoamericana deDiabetes (ALAD) Epidemiología, Diagnóstico, Control, Prevención y Tratamiento del Síndrome Metabólico en Adultos VOL. XVIII - No 1 - Año 2010 pp 25-40. 4. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for Study of obesity. Circulation. 2009;120(16):1640-5. 5. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991;14(3):173-94. 6. Miranda PJ, DeFronzo RA, Califf RM, Guyton JR. Metabolic syndrome: evaluation of pathological and therapeutic outcomes. AmHeart J. 2005;149(1):20-32. 7. Lyon CJ, Law RE, Hsueh WA. Minireview: adiposity, inflammation, and atherogenesis. Endocrinology. 2003;144(6):2195-200. 8. Chen HM, Liu ZH, Zeng CH, et al. Podocyte lesions in patients with obesity-related glomerulopathy. Am J Kidney Dis. 2006;48:772-9. 9. LuqueM, Martell N. Hipertensión y síndromemetabólico. Med Clin 2004; 123:707711. 10. Documento http://www.elsevier.es, day 23/12/2017. 11. Nolan JJ, Beerdsen P, Ludvik B, et al. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med. 1994;331:1188-93. 12. Zemel MB. Nutritional and endocrine modulation of intracellular calcium: Implications in obesity, insulin resistance and hypertension. Mol Cell Biochem. 1998;188:129-36. 13. Jacobs DB, Sowers JR, Hmeidan A, et al. Effects of weigh reduction on cellular cation metabolism and vascular resistance. Hypertension. 1993;21:308-14. 14. Nolan JJ, Beerdsen P, Ludvik B, et al. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med. 1994;331:1188-93. 15. Dyer AR1, Elliott PJ. The INTERSALT study: Relations of body mass index to blood pressure. INTERSALT cooperative research group. Hum Hypertens. 1989 Oct;3:299-308.
RkJQdWJsaXNoZXIy MTYwMjk1